Adlai Nortye Group (ANL) vs Taysha Gene Therapies (TSHA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Adlai Nortye Group (ANL) has outperformed Taysha Gene Therapies (TSHA) over the past year, gaining 796.5% versus a loss of 12.5%. Taysha Gene Therapies is the larger company by market cap ($1.44 billion vs $998.8 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANL | TSHA |
|---|---|---|
| Share price | $15.51 | $4.43 |
| Market cap | $998.81M | $1.44B |
| 1-day change | +10.39% | 0.00% |
| YTD return | +992.25% | -19.45% |
| 1-year return | +796.53% | -12.45% |
| 5-year return | — | -75.22% |
| EPS (TTM) | $-0.66 | $-0.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.25 | $7.30 |
| 52-week low | $0.879 | $3.69 |
| Distance from 52-week high | -10.09% | -39.32% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +90.20% | +193.45% |
| Average volume | 187.30K | 3.28M |
| Shares outstanding | 58.73M | 325.83M |
| Employees | 109 | 99 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANL has outperformed TSHA by 809.0 percentage points over the past year.
About Adlai Nortye Group
ANL stock →Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.
Healthcare · Biotechnology · 109 employees
About Taysha Gene Therapies
TSHA stock →Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome.
Healthcare · Biotechnology · 99 employees
ANL vs TSHA FAQ
Which is bigger, Adlai Nortye Group or Taysha Gene Therapies?
Taysha Gene Therapies (TSHA) is larger, with a market capitalization of $1.44B compared with $998.81M for Adlai Nortye Group (ANL).
Which stock has performed better over the past year, ANL or TSHA?
ANL returned +796.53% over the past 12 months, compared with -12.45% for TSHA (price return, excluding dividends). Past performance does not predict future results.
Are Adlai Nortye Group and Taysha Gene Therapies in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.